checkAd

    DGAP-Adhoc  355  0 Kommentare Evotec AG announces its intent to acquire Cyprotex PLC


    Evotec AG / Key word(s): Mergers & Acquisitions

    26.10.2016 09:00

    Disclosure of an inside information according to Article 17 MAR,
    transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
    ISIN: DE 000 566480 9, WKN 566480) today announced that it has made an
    offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist
    pre-clinical contract research organisation in ADME-Tox and DMPK
    headquartered in UK. The proposed acquisition, which has been unanimously
    recommended by the board of Cyprotex, is expected to close before year-end
    2016.

    Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate
    of 1.12) in cash for the acquisition of all 26.1 million issued and to be
    issued Cyprotex shares and the funding of all existing company debt. The
    offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of
    the past 30 trading days at AIM. The offer is intended to be implemented by
    a scheme of arrangement regulated by the UK takeover code, with already
    >50% shares secured irrevocable.


    Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
    Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
    81-242, werner.lanthaler@evotec.com


    26.10.2016 The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: Evotec AG
    Manfred Eigen Campus / Essener Bogen 7
    22419 Hamburg
    Germany
    Phone: +49 (0)40 560 81-0
    Fax: +49 (0)40 560 81-222
    E-mail: info@evotec.com
    Internet: www.evotec.com
    ISIN: DE0005664809
    WKN: 566480
    Indices: TecDAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
    Munich, Stuttgart, Tradegate Exchange

    End of Announcement DGAP News-Service

    ---------------------------------------------------------------------------



    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Evotec AG announces its intent to acquire Cyprotex PLC Evotec AG / Key word(s): Mergers & Acquisitions 26.10.2016 09:00 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this …

    Schreibe Deinen Kommentar

    Disclaimer